Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
NEW YORK , Aug. 17, 2017 -- BeyondSpring Inc. (NASDAQ Capital Markets:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that Richard Brand, Chief Financial Officer, will present at the 2017 Southern California Investor Conference on Thursday, August 24, 2017 at 11:30 A.M. Pacific Time (2:30 P.M. Eastern Time). The event will be held at the Island Hotel in Newport Beach, California.
A live webcast of the conference call will be available online which can be accessed through the Investors section of BeyondSpring’s website, http://ir.beyondspringpharma.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. An archived replay of the webcast will be available on the Company’s website after the conference.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 clinical trials in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Investor Relations: Garth Russell / Steve Silver KCSA Strategic Communications P: +1-212-682-6300 [email protected] / [email protected] Media Relations: Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 [email protected] / [email protected]
